3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
6
Gastrointestinal
2
Thoracic
1
Other
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Classical hematology
1
Conditions
Prostatic Neoplasms
1425
Carcinoma, Renal Cell
586
Urinary Bladder Neoplasms
368
Kidney Neoplasms
257
Carcinoma, Transitional Cell
190
Neoplasm Metastasis
163
Neoplasms
123
Melanoma
83
Breast Neoplasms
80
Carcinoma, Non-Small-Cell Lung
77
Testicular Neoplasms
67
Ovarian Neoplasms
62
Sarcoma
55
Urethral Neoplasms
51
Non-Muscle Invasive Bladder Neoplasms
50
Wilms Tumor
49
Lung Neoplasms
45
Colorectal Neoplasms
43
Neuroblastoma
39
Uterine Cervical Neoplasms
38
Penile Neoplasms
37
Pancreatic Neoplasms
37
Urologic Neoplasms
34
Recurrence
32
Lymphoma, Non-Hodgkin
32
Ureteral Neoplasms
28
Osteosarcoma
28
Testicular Germ Cell Tumor
26
Head and Neck Neoplasms
26
Clear-cell metastatic renal cell carcinoma
26
Interventions
pembrolizumab
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Colitis, Ulcerative
×
Genitourinary
×
Clear all
NCT07223424
2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2
Recruiting
880 enrolled